Pfizer DS3 project in Zagreb Croatia commenced in February 2022 expanding the Sisk operational area into the southeast of Europe and the Balkans
The project was undertaken by Pfizer in partnership with Sobi to produce biologically innovative drugs to treat rare diseases which will be exported to 50 markets, improving the lives of patients around the world.
| Client | Pfizer |
|---|---|
| Size/Area | 4,000 sq meters |
| Value | €140 million |
| Architect | Ekonberg doo |
The facility constructed over 3 main floors contained Production Suites and Production Support Areas, utility generation and plantrooms, laboratories, warehouse and cold chain storage areas.
It is equipped with technology to produce sophisticated medicines, measuring more than 4,000 square meters and covering 11 hectares.
The project involved a number of complexities including working in a seismic zone, constructability of heavily congested service installations, working in live environments and adjusting to the requirements of a new jurisdiction with unfamiliar supply chain. Sisk employed a team which blended local knowledge and pharmaceutical experience to meet the challenges.
The milestone of 1 million hours worked without an LTI (Lost Time Injury) was reached in June of 2024, which was a significant achievement for the entire project and especially for the Sisk team.
Due to the fact that the project was being built in an earthquake zone, new and unfamiliar construction methods were employed, including the requirement to have he structural frame constructed as a monolithic concrete frame.